Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone
This article was originally published in The Pink Sheet Daily
Executive Summary
The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.
You may also be interested in...
Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.
Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.
Financings Of The Fortnight: Despite Venture Capital Fundraising Struggles, Deals Continue
Big venture rounds for Flexion and Lux Biosciences highlight the last two weeks' financing activity.